Oxford’s Brainomix involved in new UK atrial fibrillation study
Brainomix, an Oxford based AI-powered medtech solutions firm, has announced its role in a new University of Liverpool study on post-stroke atrial fibrillation (AF).
AI systems at sites where Brainomix’s e-Stroke platform is currently deployed will collect real-time imaging data and transfer it back to researchers.
The Liverpool-Huawei Stroke Study is looking to investigate the clinical effectiveness, cost effectiveness, and acceptability of Huawei Smartwear to detect AF in patients following an acute ischemic stroke, with the main aim being to detect F quicker, leading to earlier treatment and reducing the risk of stroke re-occurring.
Read more - Oxford-based Brainomix agrees AI stroke care partnership with Blackford
Atrial fibrillation is a common heart rhythm disorder which increases the risk of stroke five-fold and is estimated to affect 24% of post-stroke patients. Its detection is critical to initiate appropriate monitoring and treatment to reduce the risk of recurrent stroke but is often challenging and unreliable.
Dr George Harston, Chief Medical & Innovation Officer at Brainomix, said: “We are pleased to be involved in the Liverpool-Huawei Stroke Study, where our e-Stroke platform can provide trial investigators with high-quality, prospectively processed descriptive baseline imaging data.”
Chief Investigator, Prof Gregory Lip, who is Price-Evans Chair of Cardiovascular Medicine and Director of the Liverpool Centre for Cardiovascular Science, said “We are delighted by this collaboration with Brainomix, which enhances our growing research portfolio into stroke and atrial fibrillation research, and would help inform clinical practice and improve our care and management of these patients.”
Read more - Oxford biotech secures FDA designation in bid to develop treatment for rare and incurable disease
